US regulators are undertaking a priority review of MSD’s Keytruda for the treatment of adult and paediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC). More: Priority review for MSD’s Keytruda for Merkel cell carcinoma Source: News
read moreHorizon Pharma says it has completed enrollment in a confirmatory Phase III trial of teprotumumab in patients living with moderate-to-severe active thyroid eye disease (TED) ahead of schedule. More: Horizon completes enrollment in TED trial early Source: News
read moreNew research has discovered a subset of men with prostate cancer who have specific faults in their tumours that significantly worsen their chances of survival, but could mean they are more likely to benefit from immunotherapy. More: Study discovers immunotherapy
read moreHospitals are gearing up to offer Novartis’ ground-breaking CAR-T therapy Kymriah to children with advanced leukaemia, after the drugmaker reached a deal with NHS England over its provision. More: NHS England strikes deal with Novartis on Kymriah Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals